The Glucagon Paradox in Next-Generation Incretin Therapy: GLP-1, GIP, and Glucagon Receptor Co-Agonism

Introduction

The treatment landscape for obesity and type 2 diabetes has changed dramatically with the emergence of incretin-based pharmacotherapy. Earlier obesity medications generally produced modest weight loss and were often limited by tolerability, safety, or durability concerns. In contrast, modern GLP-1 receptor agonists and dual incretin agonists have demonstrated clinically meaningful and sustained reductions in body weight, with additional benefits on glycemic control and cardiometabolic risk markers.

GLP-1 receptor agonists such as semaglutide established that pharmacologic activation of gut hormone pathways could produce double-digit percentage weight loss in many patients. Tirzepatide, a dual GIP and GLP-1 receptor agonist, extended this concept by demonstrating even greater weight reduction in adults with obesity or overweight. In the SURMOUNT-1 trial, tirzepatide 15 mg produced a mean weight reduction of 22.5% over 72 weeks in adults without diabetes, highlighting the potential value of multi-receptor metabolic therapy.

The next major step in this therapeutic evolution is the addition of glucagon receptor activation. This approach initially appears counterintuitive. Glucagon is classically viewed as a fasting and counter-regulatory hormone that increases hepatic glucose output through glycogenolysis and gluconeogenesis. In isolation, glucagon receptor activation could theoretically worsen hyperglycemia, particularly in patients with insulin resistance or type 2 diabetes. However, the biology of glucagon extends beyond glucose production. Glucagon also influences lipid oxidation, hepatic fat metabolism, amino acid turnover, and energy expenditure.

The central question is therefore not whether glucagon raises glucose under physiologic conditions; it does. The more clinically relevant question is whether controlled glucagon receptor activation, when paired with GLP-1 and/or GIP receptor agonism, can shift glucagon’s metabolic impact from primarily hyperglycemic toward thermogenic, lipolytic, and hepatometabolic benefit. Emerging clinical data from retatrutide and survodutide suggest that this strategy may be viable, though long-term safety, durability, and comparative effectiveness remain under active investigation.

The Biology of GLP-1, GIP, and Glucagon

GLP-1 receptor signaling

GLP-1 is an incretin hormone secreted primarily by intestinal L cells in response to nutrient intake. Pharmacologic GLP-1 receptor activation improves glucose homeostasis through glucose-dependent insulin secretion, suppression of inappropriate glucagon secretion, delayed gastric emptying, and reduced appetite. GLP-1 receptors are expressed in pancreatic islet cells, the gastrointestinal tract, vagal afferents, and brain regions involved in satiety and energy balance.

The therapeutic relevance of GLP-1 receptor activation is now well established. Its glucose-dependent insulinotropic effect lowers hemoglobin A1c with relatively low intrinsic hypoglycemia risk when not combined with insulin or sulfonylureas. Its central and gastrointestinal actions reduce caloric intake, meal size, and appetite drive. These effects explain why GLP-1 receptor agonists are useful for both type 2 diabetes and chronic weight management.

GIP receptor signaling

GIP is secreted by intestinal K cells after nutrient ingestion and, like GLP-1, stimulates glucose-dependent insulin secretion. Its role in obesity pharmacotherapy is more complex than GLP-1’s because native GIP has historically been associated with adipose biology, nutrient storage, and context-dependent effects on glucagon secretion. However, the clinical success of tirzepatide suggests that pharmacologic GIP receptor activation can enhance the efficacy of GLP-1 receptor agonism.

The precise contribution of GIP receptor activation to weight reduction remains an area of active study. Proposed mechanisms include enhanced insulinotropic activity, improved adipose tissue handling of nutrients, central effects on appetite and reward pathways, and improved tolerability or pharmacodynamic balance when combined with GLP-1 receptor agonism. The clinical point is that GIP should not be viewed simply as a weight-promoting hormone. In a dual agonist framework, GIP receptor activation appears to support clinically meaningful weight loss and glycemic improvement.

Glucagon receptor signaling

Glucagon is secreted by pancreatic alpha cells and serves as a major counter-regulatory hormone to insulin. During fasting, hypoglycemia, or physiologic stress, glucagon increases hepatic glucose production through glycogenolysis and gluconeogenesis. This role is essential for maintaining plasma glucose availability, especially for glucose-dependent tissues.

Yet glucagon also has broader metabolic actions. It promotes hepatic fatty acid oxidation, influences ketogenesis, modulates amino acid metabolism, and may increase energy expenditure. These effects become therapeutically interesting in obesity because they suggest that glucagon receptor activation could complement appetite suppression by increasing caloric expenditure and improving hepatic lipid handling. The challenge is to capture these catabolic and hepatometabolic benefits without producing unacceptable hyperglycemia.

The Glucagon Paradox

The “glucagon paradox” refers to the unexpected possibility that a hormone traditionally associated with raising blood glucose may enhance weight loss when incorporated into balanced multi-receptor agonists. In isolation, glucagon receptor activation would not be expected to serve as an ideal diabetes or obesity therapy. It could increase hepatic glucose output and worsen glycemia. However, in a co-agonist molecule, glucagon receptor activation occurs alongside GLP-1 and, in the case of retatrutide, GIP receptor activation.

This receptor balance is critical. GLP-1 receptor activation suppresses appetite, slows gastric emptying, enhances glucose-dependent insulin secretion, and helps restrain inappropriate glucagon activity. GIP receptor activation may further support insulin secretion and metabolic regulation. Within this incretin-dominant environment, glucagon receptor activation may contribute more strongly to energy expenditure, fatty acid oxidation, and hepatic lipid metabolism than to uncontrolled hyperglycemia.

In practical terms, the therapeutic objective is not to mimic unopposed glucagon excess. Rather, it is to engineer a pharmacologic signal in which glucagon’s catabolic properties are preserved while its hyperglycemic liability is buffered by incretin-mediated glucose control. This is the key conceptual difference between glucagon physiology and glucagon receptor agonism as part of a balanced incretin co-agonist.

Mechanisms That May Explain Enhanced Weight Loss

Reduced energy intake

GLP-1 receptor activation reduces appetite and food intake through hypothalamic, hindbrain, vagal, and gastrointestinal mechanisms. Patients commonly experience earlier satiety, smaller meal size, reduced hunger, and decreased preference for energy-dense foods. These effects are central to the weight loss observed with GLP-1 receptor agonists and dual incretin agonists.

When GIP and glucagon receptor activation are added, appetite regulation may become broader and more durable, although the relative contribution of each receptor remains incompletely defined. Importantly, clinical weight loss with retatrutide and tirzepatide is unlikely to be explained by one mechanism alone. These agents likely combine reduced energy intake with changes in substrate metabolism, insulin secretion, and energy expenditure.

Increased energy expenditure

One of the most important theoretical advantages of glucagon receptor activation is increased energy expenditure. Weight loss typically triggers adaptive reductions in metabolic rate, which can slow further weight reduction and promote regain. Glucagon receptor activation may partially counter this adaptation by increasing hepatic energy metabolism and possibly thermogenic pathways.

Preclinical and translational studies suggest that glucagon can increase metabolic rate and influence thermogenesis. However, the degree to which brown adipose tissue activation contributes to weight loss in humans remains uncertain. Therefore, the strongest current claim is that glucagon receptor activation may increase energy expenditure through hepatic and systemic metabolic mechanisms, but the exact human contribution of thermogenesis requires further study.

Enhanced lipid oxidation and hepatic fat metabolism

Glucagon has important effects on hepatic lipid metabolism. It can promote fatty acid oxidation and reduce hepatic lipogenesis, which may be particularly relevant for patients with obesity, insulin resistance, metabolic dysfunction-associated steatotic liver disease, or type 2 diabetes. In a multi-agonist framework, these effects may complement the weight-loss and insulin-sensitizing effects of GLP-1 and GIP receptor activation.

This hepatometabolic rationale is especially important because obesity is not merely a disorder of excess body weight. It is frequently associated with ectopic lipid deposition, hepatic steatosis, dyslipidemia, systemic inflammation, and increased cardiovascular risk. A therapy that reduces appetite while also improving liver fat metabolism could have advantages beyond weight reduction alone.

Improved metabolic flexibility

Obesity and type 2 diabetes are commonly associated with impaired metabolic flexibility, meaning the body has difficulty switching efficiently between glucose and fat oxidation. By combining incretin-mediated glucose regulation with glucagon-mediated lipid oxidation, multi-receptor agonists may help restore a more flexible metabolic state. This could allow greater mobilization and oxidation of stored fat during periods of reduced energy intake.

This mechanism remains partly theoretical but is biologically plausible. It also aligns with the observed improvements in cardiometabolic markers seen in clinical trials of incretin-based therapies.

Clinical Evidence

Semaglutide: proof of concept for high-efficacy GLP-1 therapy

Semaglutide 2.4 mg established that selective GLP-1 receptor agonism could produce substantial weight loss in adults with obesity. In STEP 1, semaglutide 2.4 mg produced a mean body-weight reduction of approximately 14.9% over 68 weeks. This trial helped redefine expectations for pharmacologic obesity treatment and provided a benchmark against which newer multi-receptor therapies are often compared.

Tirzepatide: dual GIP/GLP-1 receptor agonism

Tirzepatide demonstrated that dual incretin receptor agonism could produce greater weight loss than earlier single-receptor approaches. In SURMOUNT-1, adults with obesity or overweight without diabetes were randomized to tirzepatide or placebo for 72 weeks. Mean body-weight reduction reached 22.5% with the 15 mg dose, compared with 2.4% with placebo.

Tirzepatide does not activate the glucagon receptor. Its importance in this discussion is that it supports the broader principle that multi-receptor agonism can outperform selective GLP-1 receptor agonism. It also provides the clinical foundation for asking whether adding glucagon receptor activation can further increase efficacy.

Retatrutide: triple GIP/GLP-1/glucagon receptor agonism

Retatrutide is an investigational once-weekly triple receptor agonist that activates GIP, GLP-1, and glucagon receptors. It is the clearest clinical example of the “glucagon paradox” because it incorporates glucagon receptor activation into a molecule that has produced very large reductions in body weight.

In a phase 2 trial published in The New England Journal of Medicine, retatrutide produced substantial weight loss in adults with obesity or overweight over 48 weeks, with the highest-dose groups achieving reductions that reached up to 24.2%. These results directly challenge the assumption that glucagon receptor activation must necessarily impair weight-loss pharmacotherapy.

Retatrutide has also been studied in type 2 diabetes. In a phase 2 trial published in The Lancet, retatrutide produced clinically meaningful improvements in glycemic control and robust reductions in body weight among people with type 2 diabetes. This is important because it suggests that glucagon receptor activation, when balanced by incretin co-agonism, does not automatically negate glycemic benefit.

More recently, Lilly reported topline phase 3 TRIUMPH-1 results in adults with obesity or overweight without diabetes. In that company-reported analysis, retatrutide 12 mg produced a mean body-weight reduction of 28.3% at 80 weeks, and 45.3% of participants achieved at least 30% weight loss. Because these data were released as topline results and not yet as a full peer-reviewed manuscript, they should be interpreted as highly promising but preliminary.

Survodutide: dual GLP-1/glucagon receptor agonism

Survodutide is not a triple agonist. It is a dual GLP-1/glucagon receptor agonist. This distinction is important because survodutide helps isolate the potential contribution of glucagon receptor activation when paired with GLP-1 receptor agonism but without GIP receptor activation.

In a phase 2 dose-finding trial in adults with obesity or overweight, survodutide produced dose-dependent reductions in body weight and was described as a glucagon receptor–GLP-1 receptor dual agonist. These findings support the concept that glucagon receptor activation may be therapeutically useful when balanced by GLP-1 receptor signaling, although retatrutide currently provides the most prominent evidence for triple receptor agonism.

Comparative Interpretation

The clinical evidence suggests a stepwise pattern of increasing efficacy across incretin-based approaches:

This comparison should be interpreted cautiously. These were not all head-to-head trials. Differences in patient populations, trial duration, dose escalation, baseline weight, diabetes status, adherence, and estimand strategy limit direct comparisons. Still, the pattern is biologically and clinically provocative: adding receptor pathways appears to increase the magnitude of weight reduction.

Safety and Clinical Considerations

Gastrointestinal adverse effects

The most common adverse effects of incretin-based therapies are gastrointestinal, including nausea, vomiting, diarrhea, constipation, dyspepsia, and abdominal discomfort. These effects are often most prominent during dose escalation and may improve with slower titration or continued therapy.

Retatrutide’s phase 3 topline data reported adverse events broadly consistent with incretin-based therapies, with nausea, diarrhea, constipation, and vomiting among the most common. The 12 mg dose had higher gastrointestinal event rates and higher discontinuation due to adverse events than lower doses, emphasizing the need to balance efficacy with tolerability.

Glycemic safety

A key concern with glucagon receptor activation is hyperglycemia. However, available retatrutide data in type 2 diabetes indicate that triple agonism can improve glycemic control despite glucagon receptor activity. This likely reflects the balancing effects of GLP-1 and GIP receptor activation, including glucose-dependent insulin secretion and reduced energy intake.

Nevertheless, patients using insulin or sulfonylureas may require dose adjustments when initiating potent incretin-based therapy because improved glycemia and reduced caloric intake can increase hypoglycemia risk when combined with therapies that independently lower glucose.

Investigational status

Retatrutide is not currently an approved medication. It remains investigational pending completion of phase 3 studies, regulatory review, and publication of full safety and efficacy data. This distinction is essential in any clinical or research discussion. The existing evidence is promising, but retatrutide should not be presented as an available clinical therapy until approved by regulatory agencies.

Implications for Obesity and Metabolic Disease

The glucagon paradox has important implications for the future of obesity pharmacotherapy. Historically, obesity treatment focused primarily on reducing caloric intake. Modern incretin-based therapy still relies heavily on appetite suppression, but the addition of glucagon receptor activation may shift the model toward a broader metabolic strategy: reducing food intake while increasing energy expenditure and improving hepatic lipid metabolism.

This shift matters because obesity is biologically defended. Weight loss activates compensatory mechanisms, including increased hunger and reduced energy expenditure. Therapies that address both sides of the energy-balance equation may produce greater and more durable weight loss. Retatrutide’s clinical results suggest that combining appetite suppression with glucagon-linked catabolic signaling may be one way to achieve this.

The potential relevance extends beyond weight loss. If glucagon receptor activation improves hepatic fat metabolism, then GLP-1/glucagon or GIP/GLP-1/glucagon agonists may have particular value in patients with obesity-associated metabolic liver disease. If these agents also improve triglycerides, waist circumference, blood pressure, inflammation, and insulin resistance, they may become comprehensive cardiometabolic therapies rather than weight-loss drugs alone.

Limitations of the Evidence

Several limitations should be emphasized. First, retatrutide phase 3 data are currently available as topline company-reported results, and full peer-reviewed publication is needed. Second, retatrutide has not yet been directly compared with tirzepatide or semaglutide in large head-to-head outcome trials. Third, long-term safety data remain limited, particularly for chronic glucagon receptor activation. Fourth, the relative contributions of appetite suppression, energy expenditure, lipid oxidation, and hepatic fat reduction are not fully quantified in humans.

Finally, the optimal receptor-activation ratio is unknown. The most effective balance of GLP-1, GIP, and glucagon activity may differ by patient phenotype, diabetes status, degree of obesity, hepatic steatosis, baseline insulin resistance, and tolerability profile.

 

Frequently Asked Questions

How can glucagon help with weight loss if it raises blood sugar?

Glucagon raises glucose when acting in isolation, especially during fasting or hypoglycemia. In a multi-receptor agonist, however, glucagon receptor activation occurs alongside GLP-1 and sometimes GIP receptor activation. These incretin effects improve insulin secretion, reduce appetite, slow gastric emptying, and support glucose control. This allows glucagon’s effects on energy expenditure and lipid oxidation to become therapeutically useful while reducing its hyperglycemic liability.

Is retatrutide available clinically?

No. Retatrutide remains investigational. It has shown strong phase 2 results and promising topline phase 3 results, but it is not yet an approved medication.

Is survodutide a triple agonist?

No. Survodutide is a dual GLP-1/glucagon receptor agonist. Retatrutide is the major investigational triple agonist targeting GIP, GLP-1, and glucagon receptors.

Does glucagon receptor activation increase hypoglycemia risk?

Glucagon itself generally raises glucose, but potent incretin-based therapies can lower glucose substantially, especially when combined with insulin or sulfonylureas. The intrinsic hypoglycemia risk of incretin-based therapies is usually low, but patients on insulin or sulfonylureas may need medication adjustment.

Could these medications replace bariatric surgery?

Not necessarily. Some investigational agents are producing weight-loss results approaching surgical ranges, but bariatric surgery has longer-term outcome data and distinct metabolic effects. Medication therapy is reversible and nonsurgical but usually requires ongoing treatment to maintain weight loss.

---

References

Campbell, J. E., & Drucker, D. J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 17(6), 819–837. https://doi.org/10.1016/j.cmet.2013.04.008

Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001

Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019). Glucagon receptor signaling and lipid metabolism. Frontiers in Physiology, 10, Article 413. https://doi.org/10.3389/fphys.2019.00413

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Rosenstock, J. (2023). Triple–hormone-receptor agonist retatrutide for obesity: A phase 2 trial. The New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972

le Roux, C. W., Steen, O., Lucas, K. J., Startseva, N., Unseld, A., & Haupt, A. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomized, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology, 12(3), 162–173. https://doi.org/10.1016/S2213-8587(23)00356-X

Lilly. (2026, May 21). Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial. PR Newswire. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html

Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010

Rosenstock, J., Frías, J. P., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Milicevic, Z., Coskun, T., Hartman, M. L., & Haupt, A. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X

Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism, 31(6), 410–421. https://doi.org/10.1016/j.tem.2020.02.006